Failure to Monitor Residents on Insulin and Anticoagulant Therapy
Summary
The facility failed to monitor two residents for signs and symptoms associated with insulin therapy, and failed to monitor one of those residents for signs and symptoms of bleeding while receiving anticoagulant therapy. Resident 1 had diagnoses including type 2 diabetes, right leg cellulitis, lumbar spine spondylosis, and lymphedema, and was documented as cognitively intact for daily decision making. Resident 1 was receiving Humalog insulin by sliding scale, but the MDS nurse stated there was no order to monitor for signs and symptoms of hypoglycemia or hyperglycemia and no documented evidence that such monitoring occurred. The resident’s diabetes care plan identified risk for hypoglycemia and hyperglycemia, and the MDS nurse stated the care plan interventions should have included monitoring for those signs and symptoms. Resident 32 also had DM II and was documented as cognitively intact. The resident was receiving Insulin Lispro before meals and at bedtime by sliding scale. The MDS nurse stated Resident 32 did not have an order to monitor for signs and symptoms of hypoglycemia or hyperglycemia, and there was no documented evidence in the nurses’ progress notes that the resident was monitored for those symptoms. Resident 32’s diabetes care plan identified risk for hypoglycemia and hyperglycemia and included interventions to monitor, document, and report signs and symptoms such as sweating, tremor, tachycardia, pallor, nervousness, confusion, slurred speech, lack of coordination, and staggering gait, but the MDS nurse stated those interventions were not followed and implemented because there was no documentation that staff monitored the resident. Resident 32 was also receiving Enoxaparin Sodium injection for blood clotting prevention. The MDS nurse stated the resident should have had monitoring for bleeding, bruises, and hematoma because of Lovenox use. The anticoagulant therapy care plan directed staff to administer anticoagulants as ordered and monitor for side effects and effectiveness every shift, including reporting adverse reactions such as blood in urine or stool, bruising, sudden headaches, nausea, vomiting, lethargy, shortness of breath, and changes in mental status or vital signs. The MDS nurse stated there was no documented evidence in the nurses’ progress notes that Resident 32 was monitored for signs and symptoms of bleeding while on anticoagulant therapy.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.